Share this page
Germany09/06/2023
EHA 2023 Congress
Octapharma Update-In-Hematology
:quality(80)/f/54881/1743x1394/eeacf4e95b/eha-2023.png)
Chronic Lymphocytic Leukemia (CLL) and Beyond
Management of the Infection Burden
Friday, 9 June, 2023
16:15 - 17:45 CEST
Room: Illusion
The overall survival of patients with chronic lymphocytic leukemia (CLL) has improved significantly over the years; however, the clinical course remains highly heterogeneous, and infections continue to be a major cause of death.
Given the high risk of infection in patients with CLL, infection prophylaxis has to play a key role. Presently, immunoglobulin replacement therapy (IgRT) is recommended to patients with low IgG levels who have already experienced at least two severe infections within a year. Recent clinical developments bring novel perspectives to this approach.
During this session, the results of a real-world retrospective study analyzing the infection risk in CLL patients based on their history of infections and treatments will be discussed. Emphasis will be placed on how infections of varying degrees of severity are modulated after initiation of IgRT. Subsequently, a second study based on a sample analysis representative of the practice in Germany will detail the risk factors for infections in CLL patients and highlight the impact of the adherence to IgG substitution guidelines on infectious episodes. Then, real-world data on the use of subcutaneous immunoglobulin therapy in CLL patients suffering from antibody deficiency will be presented and therapies under development will be reviewed.
In the last part of the session, the audience and faculty will have the opportunity to exchange views and debate on challenging cases of CLL-associated infections. Questions from the audience will be answered at the end of the session.
To attendt his session, register to the EHA 2023 Hybrid Congress.
Programme
Agenda | Speaker |
|---|---|
Welcome and introduction | Chair: Stephan Stilgenbauer (Ulm, Germany) |
Identifying the Risk of Infections in CLL – Impact of Treatment and Supportive Care | Caspar da Cunha-Bang (Copenhagen, Denmark) |
Reducing the Severity of Infections Associated with CLL – The Importance of IgG Substitution Guidelines | Hartmut Link (Kaiserslautern, Germany) |
Targeting Primary Infection Prophylaxis in the Context of CLL – Daily Practice and Clinical Studies | Livio Trentin (Padua, Italy) |
Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL | All Faculty |
Closing Remarks | Stephan Stilgenbauer (Ulm, Germany) |
This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.
Meet the speakers
Chair: Stephan Stilgenbauer
Ulm University, Germany
Caspar da Cunha-Bang
Rigshospitalet, Copenhagen, Denmark
Hartmut Link
Hematology Oncology Kaiserslautern, Germany
Livio Trentin
University of Padua, Italy
Learn more about SID
Visit our information hub to learn more about secondary immunodeficiencies and hematological malignancies.
Science Hub
View more lectures about immunodeficiencies related to hematological malignancies on Science Hub.